NEW PRODUCTS
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 2073108 | PF-06802861 ( ARRY 371797 ; ARRY-797 ) | 1034189-82-6 | ≧98.0% | _1034189-82-6.png) |
| ARRY 797 (also known as ARRY 371797 or PF 06802861) is an orally active, selective p3 | ||||
| 011813 | Avoralstat | 918407-35-9 | 95.0% |  |
| Avoralstat (formerly BCX4161) is a potent small-molecule oral plasma kallikrein inhib | ||||
| 20318 | Zotizalkib ( TPX-0131 ) | 2648641-36-3 | ≧98.0% | _2648641-36-3.png) |
| TPX-0131 is a next-generation ALK inhibitor drug candidate currently being evaluated | ||||
| 822221 | IACS-13909 | 2160546-07-4 | ≧98.0% |  |
| IACS-13909 is a specific and potent allosteric inhibitor of SHP2, that suppresses sig | ||||
| 171462 | MRTX0902 | 2654743-22-1 | ≧98.0% |  |
| MRTX0902is a potent SOS1 inhibitor which can be used for the therapeutic intervention | ||||
| 20369 | Sunvozertinib ( DZD 9008 ) | 2370013-12-8 | ≧98.0% | _2370013-12-8.png) |
| Sunvozertinib, also known as DZD9008, is an oral, potent, irreversible, and selective | ||||
| 232251 | Brepocitinib ( PF-06700841 ) | 1883299-62-4 | ≧98.0% |  |
| Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1 | ||||
| 230403 | (R,S)-BI 1015550 | 1423719-27-0 | ≧98.0% | -BI_1015550_1423719-27-0.png) |
| BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of P | ||||
| 52004 | Belnacasan | 273404-37-8 | 98% | _273404-37-8.png) |
| Belnacasan is a prodrug ofVRT-043198, a caspase-1 inhibitor that was developed by Ver | ||||
| 20302 | VAS3947 | 869853-70-3 | ≧98.0% |  |
| VAS3947 is a selective inhibitor of NADPH oxidase activity in low micromolar concentr | ||||
| 232252 | Brepocitinib Tosylate | 2140301-96-6 | ≧98.0% |  |
| Brepocitinib ( PF-06700841 ) is an orally available, selective inhibitor of non-recep | ||||
| 20368 | SHMT-IN-2 | 2102681-49-0 | ≧98.0% |  |
| SHMT-IN-2 is a serine hydroxymethyltransferase (SHMT) inhibitor, potently inhibiting | ||||